达雷妥尤单抗治疗难治性ANCA相关性血管炎
本文报告两例严重难治性ANCA相关性血管炎患者,在接受利妥昔单抗和环磷酰胺诱导治疗后仍存在肾脏和肺部表现,接受4至8剂1800 mg达雷妥尤单抗治疗。两例患者临床和免疫学均改善,血清ANCA水平及总IgG显著下降,仅发生轻度不良事件。作者认为达雷妥尤单抗安全有效,但需前瞻性临床试验确立安全性和疗效。
要点
- 两例难治性AAV患者接受4至8剂1800 mg达雷妥尤单抗后临床缓解。
- 临床改善伴随血清ANCA水平及总IgG显著下降,提示浆细胞清除。
- 仅发生轻度不良事件,包括低丙种球蛋白血症和上呼吸道感染。
核心结论
- 达雷妥尤单抗在两例严重难治性AAV患者中安全且有效诱导缓解,需前瞻性临床试验确立安全性和疗效。
研究设计与样本
- 本文报告两例严重危及生命的AAV患者,尽管接受利妥昔单抗和环磷酰胺诱导治疗,仍存在肾脏和肺部表现,接受4至8剂1800 mg达雷妥尤单抗治疗,并随访临床和免疫学反应。
主要发现
- 第一例为髓过氧化物酶-ANCA阳性显微镜下多血管炎,达雷妥尤单抗治疗后肺炎和胸膜炎消退、肾功能稳定。
- 第二例为蛋白酶3-ANCA阳性肉芽肿性多血管炎,伴弥漫性肺泡出血需体外膜肺氧合(ECMO)和急性肾衰竭需肾脏替代治疗,达雷妥尤单抗治疗后脱离ECMO、机械通气和透析并出院回家。
- 临床改善伴随血清ANCA水平及总IgG显著下降,提示浆细胞清除。
- 除CD38+自然杀伤细胞清除外,血液白细胞水平未受达雷妥尤单抗显著影响。
- 仅发生轻度不良事件,如低丙种球蛋白血症和上呼吸道感染。
临床怎么用
- 作者认为达雷妥尤单抗在严重难治性AAV中安全且有效诱导缓解,需前瞻性临床试验确立安全性和疗效。
局限性
- 本文仅报告两例患者。
- 作者结论指出需前瞻性临床试验确立安全性和疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options. One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which depletes autoantibody-secreting plasma cells.Methods We treated two patients with severe life-threatening AAV with renal and pulmonary manifestation despite induction therapy with rituximab and cyclophosphamide with four to eight doses of 1800 mg daratumumab. We followed clinical and immunological responses.Results The first patient with myeloperoxidase-ANCA-positive microscopic polyangiitis had resolution of pneumonitis and pleuritis and stabilisation of kidney function after daratumumab. The second patient with proteinase 3-ANCA-positive granulomatosis with polyangiitis, diffuse alveolar haemorrhage necessitating extracorporeal membrane oxygenation (ECMO) and acute kidney failure, requiring kidney replacement therapy, was weaned off ECMO, mechanical ventilation and dialysis and discharged home after daratumumab. Clinical improvement was paralleled by a strong reduction in serum ANCA levels as well as total IgG, indicating depletion of plasma cells. Apart from the depletion of CD38+ natural killer cells, blood leucocyte levels were not notably influenced by daratumumab. Only mild adverse events, such as hypogammaglobulinaemia and an upper respiratory tract infection occurred.Conclusion Daratumumab was safe and effective in inducing remission in two patients with severe treatment-refractory AAV, warranting prospective clinical trials to establish safety and efficacy.
引用
- Ostendorf L, Burns M, Wagner DL, et al. Daratumumab for the treatment of refractory ANCA-associated vasculitis. RMD Open. 2023. PMID: 36627149. doi:10.1136/rmdopen-2022-002742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。